-
2
-
-
0029145541
-
Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme
-
Chetwynd J, Brunton C, Blank M et al. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. NZ Med J 1995;108:364-366.
-
(1995)
NZ Med J
, vol.108
, pp. 364-366
-
-
Chetwynd, J.1
Brunton, C.2
Blank, M.3
-
3
-
-
0035958778
-
Prevalence of hepatitis B and C infection in a methadone clinic population: Implications for hepatitis B vaccination
-
Carter H, Robinson G, Hanlon C et al. Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. NZ Med J 2001;114:324-6.
-
(2001)
NZ Med J
, vol.114
, pp. 324-326
-
-
Carter, H.1
Robinson, G.2
Hanlon, C.3
-
4
-
-
0032756280
-
Modelling the hepatitis C virus epidemic in Australia
-
Law MG. Modelling the hepatitis C virus epidemic in Australia. J Gastroenterol Hepatol 1999;14:1100-7.
-
(1999)
J Gastroenterol Hepatol
, vol.14
, pp. 1100-1107
-
-
Law, M.G.1
-
5
-
-
0030885637
-
Natural history of hepatitis C
-
Seef LB. Natural history of hepatitis C. Hepatology 1997;26(Suppl. 1): 21S-8.
-
(1997)
Hepatology
, vol.26
, Issue.SUPPL. 1
-
-
Seef, L.B.1
-
6
-
-
0001445884
-
Statement management of hepatitis C
-
National Institutes of Health Consensus Development Conference Panel. Statement Management of Hepatitis C. Hepatology 1997;26(Suppl.1): 2S-10.
-
(1997)
Hepatology
, vol.26
, Issue.SUPPL.1
-
-
-
7
-
-
0033799722
-
Estimating future hepatitis C morbidity, mortality, and costs in the United States
-
Wong JB, McQuillan GM, McHutchison et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-9.
-
(2000)
Am J Public Health
, vol.90
, pp. 1562-1569
-
-
Wong, J.B.1
McQuillan, G.M.2
McHutchison3
-
8
-
-
0031748381
-
Health care costs of a continuing epidemic of hepatitis C virus infection among injecting drug users
-
Brown K, Crofts N. Health care costs of a continuing epidemic of hepatitis C virus infection among injecting drug users. Aust NZ J Public Health 1998;22:384-8.
-
(1998)
Aust NZ J Public Health
, vol.22
, pp. 384-388
-
-
Brown, K.1
Crofts, N.2
-
9
-
-
30244569635
-
Economic analyses for hepatitis C: A review of Australia's response
-
Lowe D, Cotton R, eds. ch. 7. Canberra: Department of Health and Aged Care, Commonwealth of Australia
-
Shiell A. Economic analyses for hepatitis C: a review of Australia's response. In: Lowe D, Cotton R, eds. Hepatitis C: a review of Australia's response, ch. 7. Canberra: Department of Health and Aged Care, Commonwealth of Australia, 1999.
-
(1999)
Hepatitis C: A Review of Australia's Response
-
-
Shiell, A.1
-
10
-
-
0032562295
-
Hepatitis B virus carrier prevalence in New Zealand: Population estimates using the 1987 police and customs personnel survey
-
Blakely T, Salmond C, Tobias M. Hepatitis B virus carrier prevalence in New Zealand: population estimates using the 1987 police and customs personnel survey. NZ Med J 1998;111:142-4.
-
(1998)
NZ Med J
, vol.111
, pp. 142-144
-
-
Blakely, T.1
Salmond, C.2
Tobias, M.3
-
11
-
-
0032502422
-
Chronic hepatitis B virus infection in South Auckland
-
Gane E. Chronic hepatitis B virus infection in South Auckland. NZ Med J 1998;111:120-3.
-
(1998)
NZ Med J
, vol.111
, pp. 120-123
-
-
Gane, E.1
-
12
-
-
0028872317
-
Ethnic differences in the prevalence of anti-hepatitis C antibodies and hepatitis B surface antigen in Israeli blood donors by age, sex, country of birth and origin
-
Bar-Shany S, Green MS, Slepon R et al. Ethnic differences in the prevalence of anti-hepatitis C antibodies and hepatitis B surface antigen in Israeli blood donors by age, sex, country of birth and origin. J Viral Hepatitis 1995;2:139-44.
-
(1995)
J Viral Hepatitis
, vol.2
, pp. 139-144
-
-
Bar-Shany, S.1
Green, M.S.2
Slepon, R.3
-
13
-
-
0032570368
-
Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations
-
Kemp R, Miller J, Lungley S et al. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations. NZ Med J 1998;111:50-3.
-
(1998)
NZ Med J
, vol.111
, pp. 50-53
-
-
Kemp, R.1
Miller, J.2
Lungley, S.3
-
14
-
-
0033607711
-
Methadone maintenance treatment: Outcomes from the Otago methadone programme
-
Dore GM, Walker JD, Paice JR et al. Methadone maintenance treatment: outcomes from the Otago methadone Programme. NZ Med J 1999;112:442-5.
-
(1999)
NZ Med J
, vol.112
, pp. 442-445
-
-
Dore, G.M.1
Walker, J.D.2
Paice, J.R.3
-
15
-
-
0028823771
-
Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal
-
Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995;22:1863-73.
-
(1995)
Hepatology
, vol.22
, pp. 1863-1873
-
-
Dusheiko, G.M.1
Roberts, J.A.2
-
16
-
-
0028918747
-
Cost-effectiveness of interferon alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B
-
Wong JB, Koff RS, Tine F et al. Cost-effectiveness of Interferon alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Int Med 1995;122:664-75.
-
(1995)
Ann Int Med
, vol.122
, pp. 664-675
-
-
Wong, J.B.1
Koff, R.S.2
Tine, F.3
-
17
-
-
0032731788
-
Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C
-
Younossi ZM, Singer ME, McHutchison JG et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318-23.
-
(1999)
Hepatology
, vol.30
, pp. 1318-1323
-
-
Younossi, Z.M.1
Singer, M.E.2
McHutchison, J.G.3
-
18
-
-
0034124763
-
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C
-
Wong JB, Poynard T, Ling MH et al. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol 2000;95:1524-30.
-
(2000)
Am J Gastroenterol
, vol.95
, pp. 1524-1530
-
-
Wong, J.B.1
Poynard, T.2
Ling, M.H.3
-
19
-
-
0034177475
-
Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C
-
Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med 2000;108:366-73.
-
(2000)
Am J Med
, vol.108
, pp. 366-373
-
-
Wong, J.B.1
Davis, G.L.2
Pauker, S.G.3
-
21
-
-
0028998145
-
Clinical outcomes after transfusion-associated hepatitis C
-
Tong MJ, El-Farra NS, Reikes AR et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
-
(1995)
N Engl J Med
, vol.332
, pp. 1463-1466
-
-
Tong, M.J.1
El-Farra, N.S.2
Reikes, A.R.3
-
22
-
-
0034802218
-
Estimating progression to cirrhosis in chronic hepatitis C virus infection
-
Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16.
-
(2001)
Hepatology
, vol.34
, pp. 809-816
-
-
Freeman, A.J.1
Dore, G.J.2
Law, M.G.3
-
23
-
-
84990602616
-
Mortality of intravenous drug users: Attenders of the Wellington drug clinic, 1972-89
-
Dukes PD, Robinson GM, Robinson BJ. Mortality of intravenous drug users: attenders of the Wellington drug clinic, 1972-89. Drug Alcohol Rev 1992;11:197-201.
-
(1992)
Drug Alcohol Rev
, vol.11
, pp. 197-201
-
-
Dukes, P.D.1
Robinson, G.M.2
Robinson, B.J.3
-
24
-
-
30244440565
-
-
This publication uses the Australian version of ICD 9-CMA-II. Wellington: Ministry of Health
-
Ministry of Health. Mortality and demographic data 1996. This publication uses the Australian version of ICD 9-CMA-II. Wellington: Ministry of Health, 1997.
-
(1997)
Mortality and Demographic Data 1996
-
-
-
26
-
-
0028047786
-
The cost-effectiveness of alpha interferon in the treatment of chronic active hepatitis C
-
Shiell A, Briggs A, Farrell GC. The cost-effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994;160:268-72.
-
(1994)
Med J Aust
, vol.160
, pp. 268-272
-
-
Shiell, A.1
Briggs, A.2
Farrell, G.C.3
-
28
-
-
4644345404
-
Gaining control of the hepatitis C virus epidemic in Australia
-
Crofts N, Dore G, Locarnini S, eds. ch. 22. Melbourne: IP Communications
-
Crofts N, Wodak A. Gaining control of the hepatitis C virus epidemic in Australia. In: Crofts N, Dore G, Locarnini S, eds. Hepatitis C: an Australian perspective, ch. 22. Melbourne: IP Communications, 2001.
-
(2001)
Hepatitis C: An Australian Perspective
-
-
Crofts, N.1
Wodak, A.2
-
29
-
-
0028933065
-
Methadone maintenance treatment: Coming of age in New Zealand
-
Sellman D, Deering D, Robinson G. Methadone maintenance treatment: coming of age in New Zealand. NZ Med J 1995;108:128-30.
-
(1995)
NZ Med J
, vol.108
, pp. 128-130
-
-
Sellman, D.1
Deering, D.2
Robinson, G.3
-
30
-
-
0023092811
-
Compensated cirrhosis: Natural history and prognostic factors
-
Gines P, Quinterro E, Arroyo V et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-28.
-
(1987)
Hepatology
, vol.7
, pp. 122-128
-
-
Gines, P.1
Quinterro, E.2
Arroyo, V.3
|